Author: openjargon

Reliance Worldwide Corporation Ltd (ASX: RWC), in its own words, had a “challenging first half”, reporting this week that both sales and profits had fallen.

But that has, at least in the eyes of the team at Macquarie, created a buying opportunity for a company they see as fundamentally sound.

So let’s have a look at the first-half results.

Falls across the board

Reliance said earlier this week that net sales fell 4.6% to US$645.4 million, while net profit fell 34.9% to US$34.7 million.

The plumbing supplies company also announced an interim dividend of US2 cents, down from US2.5 cents, and a buyback of US$15.3 million, which it said would be the equivalent of another US2 cents per share in value.

A lot of the negative impact during the half, the company said, was caused by US tariffs.

The company said:

The expected full year net impact of tariffs in FY26 is in the range of US$25 million to US$30 million, with the impact weighted to the first half of FY26. The benefits from the transfer of product sourcing away from China to lower tariff countries, coupled with price adjustments and cost reduction measures, will continue to flow through in the second half of FY26.

The company’s Chief Executive, Heath Sharp, said it was a difficult start to the year.

He added:

The first half has been particularly challenging as we have dealt with the twin impacts of US tariffs and weak end markets. However, we are really pleased with the progress we have made with our key strategic initiatives, which have further strengthened the business and mean we are well placed to benefit from an upturn in volumes. While residential remodelling and new construction markets remained subdued, we have made significant progress on a number of strategic initiatives. We commissioned our new assembly facility in Poland and finalised plans for a new facility in Mexico which will support activity in the Americas and lower the impact of associated tariffs. During the half we also launched new product ranges with key distributors in Germany, France and Italy, while SharkBite Max was launched nationwide across Australia.

The company said it expected trading conditions for the second half of the year to be “broadly consistent” with the first half.

Shares looking cheap

The team at Macquarie have looked at the result and believes there’s room for significant share price recovery.

They said the company looks well-positioned for volume recovery alongside improvements in pricing, “so we believe any indication of volume recovery will be positive for the stock”.

The Macquarie team added:

This was a disappointing result, with known issues lingering longer than expected. At its core, Reliance is still executing well in a tough context. We believe valuation remains attractive given the leverage to an improvement in the volume outlook.

Macquarie has a price target of $4.75 on Reliance shares compared with $3.50 currently. If the price target were achieved, it would represent a total shareholder return of 37% including dividends.

The post After being sold down on weak results, one broker thinks Reliance Worldwide is a good buy appeared first on The Motley Fool Australia.

More reading

• Why Reliance, Santana Minerals, Sims, and Treasury Wine shares are falling today
• Reliance Worldwide half-year earnings: profit falls, dividend steady

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Magellan Financial Group Ltd (ASX: MFG) share price is in focus today after the company delivered a steady interim result, with operating profit holding firm at $83.1 million and a 50% lift in fully franked dividends to 39.5 cents per share.

What did Magellan Financial Group report?

• Assets under management (AUM) rose 3% to $39.9 billion at 31 December 2025
• Operating earnings per share increased 5% to 48.6 cents
• Operating profit was $83.1 million, unchanged from 1H25
• Strategic partnership income surged 109% to $25.7 million
• Investment management revenue fell 17% to $106.9 million
• Interim dividend jumped 50% to 39.5 cents per share, fully franked

What else do investors need to know?

Magellan maintained a strong capital position at the end of December, holding $504 million in liquid assets and no debt. Share buy-backs continued, with $38.4 million returned to shareholders during the half.

Net flows were positive for the institutional segment thanks to inflows into Airlie Australian Equities and Global Listed Infrastructure. Meanwhile, retail outflows stabilised while new client and product wins, especially through Vinva, added diversity to the income stream.

Recent investments in leadership, technology and governance are aimed at supporting scalable, operationally robust growth across Magellan Investment Partners, which also completed a rebrand in the half.

What’s next for Magellan Financial Group?

Looking forward, Magellan plans to expand its global distribution, especially in Asia Pacific, North America, and Europe, while continuing to focus on performance and operational efficiency. Further innovation and investment in automation and AI are on the agenda, along with ongoing development of strategic partnerships.

The company remains committed to returning capital to shareholders through dividends and share buy-backs, while carefully assessing future growth and investment opportunities. Management has highlighted sustaining and growing institutional client relationships as a key priority for the second half.

Magellan Financial Group share price snapshot

Over the pat 12 months, Magellan Financial Group shares have declined 19%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post Magellan Financial Group grows dividend as steady 1H26 results land appeared first on The Motley Fool Australia.

More reading

• Fletcher Building shares steady on half-year results and construction exit
• Nickel Industries lifts 2026 quota, driving stronger outlook and margins
• Santos delivers strong 2025 full year results and higher dividends
• Vicinity Centres FY26 earnings: Profit jumps, premium assets drive growth
• TechnologyOne upgrades earnings guidance on AI and SaaS+ momentum

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Shares in Nib Holdings Ltd (ASX: NHF) are higher in early morning trade after the health insurance provider released an update following market close yesterday.

At the time of writing, the Nib share price is up 3.45% to $6.60.

Here is what investors need to know.

Premium increases confirmed for 2026

In an ASX announcement, Nib confirmed that its private health insurance premiums will rise by an average of 5.47%.

The increase follows approval from the Federal Minister for Health and Aged Care.

Management said the changes reflect ongoing cost pressures across the healthcare system. These include higher hospital and medical costs, increased use of services, and broader inflationary impacts.

The company noted that more than half of its policyholders will see increases of $3.80 per week or less.

Chief Executive Officer Ed Close said Nib remains focused on affordability and value, while continuing to manage rising claims costs.

During FY25, the group paid $2.3 billion in claims, an increase of almost 9% on the prior year. The company also recorded more than 400,000 hospital admissions and 4.3 million visits to medical providers.

Momentum and key price levels

Looking at the chart, Nib shares have trended lower since late 2025 after peaking above $8 during the year.

The stock closed at $6.38 on Tuesday and is hovering around $6.60 in early trade. Over the past 12 months, it has traded between $5.82 and $8.26.

On the daily chart, Nib is trading near the lower end of that range. The price is closer to the lower Bollinger Band, suggesting softer short-term momentum.

The relative strength index (RSI) is around 40, placing the stock near oversold territory but not at extreme levels. This suggests selling pressure may be easing, though momentum remains weak.

The $5.80 to $6 zone has acted as support over the past year. On the upside, resistance appears near $7, with further resistance around $7.50 based on prior trading activity.

With the shares closer to support than their 12-month high, the next move may hinge on whether support holds.

What investors will be watching next

Premium adjustments are a normal part of the private health insurance cycle and are closely linked to claims trends and healthcare cost inflation.

While higher premiums can support revenue growth, investors will also be monitoring policyholder retention and membership growth in the months ahead.

Nib is scheduled to release its half-year results on Monday, 23 February. The update will provide further detail on margins, claims trends, and management’s outlook for the remainder of the year.

The post Why Nib shares are on the move after its latest update appeared first on The Motley Fool Australia.

More reading

• Why Nib shares are edging higher after today’s update

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Santos Ltd (ASX: STO) share price is in focus today after the energy company reported strong base business performance for the full year 2025, delivering $1.8 billion in free cash flow and declaring a final dividend of US 10.3 cents per share.

What did Santos report?

• Sales revenue of $4.9 billion from 93.5 million barrels of oil equivalent (mmboe) in sales volumes
• Underlying net profit after tax (NPAT) of $898 million
• Free cash flow from operations of $1.8 billion
• EBITDAX of $3.4 billion
• Final dividend of US 10.3 cents per share (total 2025 dividends: US 23.7 cents per share, representing $770 million)
• Unit production costs of $6.78 per boe, the lowest in a decade (excluding Bayu Undan)

What else do investors need to know?

Santos achieved record personal safety performance in 2025 and reached its 2030 emissions reduction target five years early, mainly due to its Moomba carbon capture and storage (CCS) project. The company remains in a solid financial position, with gearing at 21.5% excluding leases and strong liquidity of $4.3 billion.

Operationally, Santos delivered high reliability across its key assets, commenced production at Barossa and Darwin LNG earlier than planned and within budget, and continued disciplined cost control with the best unit production costs in ten years.

What’s next for Santos?

Santos is targeting further growth with the ramp up of Pikka phase 1 expected to deliver first oil by late Q1 2026 and reach full output in Q2. The company has also indicated a head count reduction of around 10% to rightsize the business as major projects become part of the base.

Guidance for 2026 is unchanged, with production and sales volumes expected in the range of 101 to 111 mmboe, unit production costs of $6.95 to $7.45 per boe, and total capital expenditure of approximately $1.95 to $2.15 billion. Santos is also pursuing new growth and decarbonisation opportunities to further strengthen its portfolio.

Santos share price snapshot

Over the past 12 months, Santos shares have declined 3%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post Santos delivers strong 2025 full year results and higher dividends appeared first on The Motley Fool Australia.

More reading

• Fletcher Building shares steady on half-year results and construction exit
• Nickel Industries lifts 2026 quota, driving stronger outlook and margins
• Magellan Financial Group grows dividend as steady 1H26 results land
• Vicinity Centres FY26 earnings: Profit jumps, premium assets drive growth
• TechnologyOne upgrades earnings guidance on AI and SaaS+ momentum

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Vicinity Centres (ASX: VCX) share price is in focus after the company posted a $805.6 million statutory net profit for 1H FY26, up 63.5% from the prior period, with a 4.8% uplift in net tangible assets per security.

What did Vicinity Centres report?

• Statutory net profit after tax: $805.6 million (1H FY25: $492.6m)
• Funds from operations (FFO): $351.0 million, up 2.0%
• Distribution per security: 6.20 cents, up 4.2%
• Comparable net property income (NPI) growth: +3.7%
• Net tangible assets (NTA) per security: $2.52, up 4.8%
• Portfolio occupancy: 99.6%

What else do investors need to know?

Vicinity Centres continued its strategy of shifting towards premium retail assets, with premium assets now making up 66% of the portfolio’s value. Key moves included securing the remaining 75% interest in Brisbane’s Uptown centre for $212 million, funded by divestments of non-strategic assets at a blended premium to book value.

Development plans are progressing, including the successful Stage 1 opening of Chatswood Chase and ongoing projects at Chadstone and Galleria. Strong leasing activity saw portfolio occupancy reach a record 99.6%, and leasing spreads move up to 4.6%, supporting future rent growth.

What’s next for Vicinity Centres?

The group expects full-year FFO and AFFO to be at the top end of its guidance. Management is targeting continued investment in premium assets, with around $400 million allocated to capital expenditure in FY26 and a focus on mixed-use development opportunities. Comparable NPI growth is now expected to be around 3.5%, with development-related rent losses factored into guidance.

Vicinity’s disciplined capital management aims to maintain flexibility for further investment, while its latest acquisitions and developments seek to boost income growth and portfolio value.

Vicinity Centres share price snapshot

Over the past 12 months, Vicinity Centres shares have risen 14%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post Vicinity Centres FY26 earnings: Profit jumps, premium assets drive growth appeared first on The Motley Fool Australia.

More reading

• Fletcher Building shares steady on half-year results and construction exit
• Nickel Industries lifts 2026 quota, driving stronger outlook and margins
• Magellan Financial Group grows dividend as steady 1H26 results land
• Santos delivers strong 2025 full year results and higher dividends
• TechnologyOne upgrades earnings guidance on AI and SaaS+ momentum

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Macquarie Group Ltd (ASX: MQG) share price has been on the move this month as the global investment bank reported its FY26 third-quarter update.

Macquarie’s earnings result is influenced by four different divisions – its banking and financial services (BFS) segment, Macquarie Asset Management (MAM), investment banking (Macquarie Capital) and the commodities and global markets (CGM) segment.

The ASX financial share reported that in the three months to December 2025, MAM’s net profit was up “substantially”, BFS’ net profit rose slightly, CGM’s net profit rose “substantially” and Macquarie Capital’s net profit grew “substantially”.

Is the Macquarie share price attractive?

Ultimately, UBS thinks the answer is yes – it has a buy rating on the business, with a price target of $235.

A price target is where analysts think the share price of a business will be in 12 months from the time of the investment call. Therefore, investors think the business could rise by 7% within a year.

UBS said that the third quarter update appeared “satisfactory overall”, with improved guidance for CGM, where income is now expected to increase rather than remain flat. However, this is partially offset by a “higher-than-anticipated tax rate” for FY26, which suggests an additional tax expense of around $250 million compared to UBS estimates, equating to an impact of around 5.5% on projected cash net profit.

The broker then analysed the commentary on the ASX financial share’s divisions:

Commentary around the divisional performance in 3Q26 reads positively, in our view. Mkts facing businesses’ (MAM & Mac Cap) result was substantially up on pcp [prior corresponding period] (25%+). CGM commentary notes improved performances from Asset Finance and a stronger performance from Commodities compared to a subdued pcp, primarily due to increased contributions from North American Power, Gas and Emissions, and Resources.

Higher opex [operating expenditure] from investments in the CGM platform is continuing. Mac Cap substantially up on asset realisations and private credit portfolio. BFS continues to grow its deposit and lending franchise well above market, albeit Macquarie calling out mkt and portfolio mix continuing to drive NIM lower, likely offset by further operating leverage coming through.

MAM (ex NA [North America] & Europe public mkts business) benefiting from strong performance fees, which is likely to continue.

Expectations for FY26

UBS noted that MAM’s base fees are expected to be “broadly in line”, though net other operating income is expected to be up significantly.

BFS is expected to see ongoing growth in the loan portfolio and deposit profits in FY26.

Macquarie Capital’s transaction activity is expected to be “in-line”. The private credit portfolio and FY26 second-half asset realisations are expected to support investment-related income to be “broadly in line”.

In CGM, commodities income is expected to be up, while volatility may create opportunities, according to UBS.

The Macquarie share price is valued at 18.4x FY26’s estimated earnings, at the time of writing, based on UBS’ forecast of earnings per share (EPS) of $11.85 for the 2026 financial year.

The post Do experts think the Macquarie share price is a buy? appeared first on The Motley Fool Australia.

More reading

• Where to invest $10,000 in ASX shares right now
• Qube Holdings board backs $11.7bn Macquarie takeover at 27.8% premium
• How to make a $50,000 passive income from ASX shares
• 3 blue-chip ASX 200 shares I would buy and hold
• How I would build an income portfolio that lasts a lifetime

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Golden Horse Minerals Ltd (ASX: GHM) put out a cheeky press release this week, saying they’d started the year “at a gallop” with visible gold in their first exploration hole at the Hopes Hill prospect.

The release caught the eye of the team at Shaw and Partners, who said the find was a “significant breakthrough”.

So what exactly did they report?

Golden Horse said this week that their first diamond drill hole had intersected visible gold at a depth of 200m under the previously-mined Hopes Hill pit, which has previously produced 216,000 ounces of gold at a grade of 2.4 grams per tonne.

The company cautioned that visible gold should not be considered a substitute for laboratory tests.

Other results of note included a 6.6m intersection at a grade of 2.6 grams per tonne from a depth of 379.5m at Hopes Hill Main and 10m at 1.2 grams per tonne from 27m at Hopes Hill North.

The company said it had mobilised a second diamond drill rig and a third reverse circulation rig at the site to expedite the more than 125km drilling program already underway.

Golden Horse Managing Director Nicholas Anderson said it was a great result so far.

With the very first hole drilled at Hopes Hill for 2026, we are thrilled to report that we have intercepted visible gold in 26HHDD001 which is a testament to our belief in the potential of this mineralised system. Whilst following geological best practice, we took the additional steps of comprehensively assaying around the visible gold to ensure we gain a detailed understanding of the gold deportment. Of the 156 re-assays, over half graded above 5.0 grams per tonne of gold with multiple +10 grams per tonne assays to 63.3 grams per tonne highlighting the upside we see at Hopes Hill. What is particularly exciting is this high-grade mineralisation is located within the footwall package, which was previously thought to have hosted lower grade mineralisation. We backed ourselves and swung the rig onto a new hole to test our geological model, and to intersect visible gold in a rock unit outside the conventional ‘mine geology corridor’ is a fantastic outcome for the company.

Shares are looking cheap

Shaw and Partners, in a research note sent to clients this week, said the visible gold was significant as it occurred in an area previously discounted as a primary gold target.

The broker has a $1.50 price target on Golden Horse shares, compared with the current price of 69 cents. The stock has increased from lows of 21 cents over the past year.

Golden Horse Minerals was valued at $185.7 million at the close of trade on Tuesday.

The post This gold explorer has more than tripled, but could double again one broker says appeared first on The Motley Fool Australia.

More reading

• ASX gold shares go crazy as gold price rips toward US$5,000 on Friday
• Considering ASX small-cap gold shares? Expert advice on how to decide

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The TechnologyOne Ltd (ASX: TNE) share price is in focus today after Australia’s largest ERP SaaS company lifted its FY26 profit guidance by 5 percentage points, targeting 18% to 20% profit before tax (PBT) growth and 16% to 18% annual recurring revenue (ARR) growth, fuelled by strong demand for its AI-powered SaaS+ offering.

What did TechnologyOne report?

• Upgraded FY26 PBT growth guidance to 18%–20%, up from the previous 13%–17% range
• ARR growth guidance lifted to 16%–18%
• Significant investment of $8–$9 million in AI Showcase events for H1 FY26
• First-half FY26 PBT growth expected in the high single digits due to phasing of investments
• Retirement of Non-executive Director Clifford Rosenberg after 7 years of service

What else do investors need to know?

TechnologyOne credited its upgraded outlook to the successful momentum of its SaaS+ products and forthcoming AI-driven innovations. The company said customer demand remains strong in Australia, New Zealand, and the UK, giving management confidence to aim for the top end of its new guidance range.

A key focus this half has been strategic investment in AI product launches, expected to provide future commercial opportunities but resulting in a slower first-half profit growth. Management stated that growth will be back-weighted, with a strong second half anticipated.

What did TechnologyOne management say?

Ed Chung, CEO and Managing Director, said:

SaaS+ and our products turbocharged through AI are our not so secret weapons, giving us the confidence to increase PBT growth to 18% to 20%, upgraded from our prior range of 13% to 17%, as well as guiding to ARR growth of 16% to 18%. We are targeting the top end of the guidance range for both PBT and ARR.

What’s next for TechnologyOne?

Looking ahead, TechnologyOne expects to maintain its disciplined growth rhythm as it continues transitioning from a SaaS business to its next-generation SaaS+ model. Management says recent investments in AI and international expansion are setting up the business for sustained profit and revenue growth.

Investors can expect more updates on product launches and new customer wins in FY26, as the company looks to capitalise on rising demand for cloud-based ERP solutions.

TechnologyOne share price snapshot

Over the past 12 months, TechnologyOne shares have declined 33%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post TechnologyOne upgrades earnings guidance on AI and SaaS+ momentum appeared first on The Motley Fool Australia.

More reading

• SGH Ltd confirms $32.35 per share BlueScope bid
• The Lottery Corporation posts steady earnings and dividend for 1H26
• Dexus posts $348.5m half-year profit as property values lift
• Telix Pharmaceuticals files European application for brain cancer imaging
• Netwealth earnings: 24% revenue jump and record inflows

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Technology One. The Motley Fool Australia has recommended Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

These 2 ASX healthcare shares have had an ordinary start to 2026.

Telix Pharmaceuticals Ltd (ASX: TLX) and Neuren Pharmaceuticals Ltd (ASX: NEU) shares have lost 21% and 31% respectively this year so far.

However, both ASX healthcare shares offer exposure to innovative healthcare solutions with meaningful growth runways. Brokers tip explosive upside for the ASX biotech shares. Let’s find out why.

Telix Pharmaceuticals Ltd (ASX:TLX)

The price of this ASX healthcare share has delivered standout gains over the past 12 months, peaking at $31.97 almost a year ago. Since then, Telix has dropped 67% in value to $8.84 at the time of writing.

Telix develops radiopharmaceuticals for cancer diagnosis and treatment, blending biotech innovation with specialised manufacturing and global distribution.

What sets Telix apart is its shift from development-stage hopeful to commercial operator. As approvals turn into broader clinical use, revenue can ramp quickly, without rebuilding the platform each time.

Growth now hinges on adoption and market penetration, not economic cycles. That brings volatility. But it also gives investors exposure to a healthcare niche where innovation can flow straight through to earnings.

Investors have been drawn to the company’s accelerating revenue from its prostate cancer imaging product Illuccix. Recent financial results showed strong revenue growth and improving profitability.

However, the risks are real. Biotech companies remain vulnerable to regulatory hurdles, trial delays, and shifting investor sentiment. The ASX healthcare also continues to invest heavily in research and development. This means earnings can fluctuate as it balances growth with cost discipline.

Most brokers have a positive recommendation on the ASX healthcare share. Citi just reiterated its buy rating on Telix with a price target of $34. This suggests a massive 285% upside.

TD Cowen also has a buy rating but lowered its price target from $25 to $20, which still points to a possible gain of 126%.

Neuren Pharmaceuticals Ltd (ASX: NEU)

Neuren’s path has been more uneven. After reaching significant highs in 2024, the $2 billion ASX healthcare share retreated sharply. Since reaching a 52-week high of $22.99 in October, it has lost 44% to $12.80 at the time of writing.

Despite this, the company has continued to generate royalty income from DAYBUE, its approved therapy for Rett syndrome. Growing royalties provide a meaningful revenue base and help distinguish Neuren from earlier-stage biotech peers that rely purely on trial outcomes.

Looking ahead, much of Neuren’s investment case rests on its broader pipeline, particularly the development of NNZ-2591 for multiple rare neurological disorders. Phase 3 trial progress and further regulatory engagement could act as powerful share price catalysts if results are positive.

Yet the risks are equally clear. Biotech valuations can swing dramatically on clinical updates, and pipeline programs remain inherently uncertain. Neuren’s share price volatility over the past year is a reminder that even companies with approved products are not immune from market re-rating.

Most brokers see the ASX biotech stock as a strong buy. They have set a 12-month price target of $23.74, which points to a 85.5% plus.

Analysts at Bell Potter see significant value in this ASX healthcare share at current levels. Last week, the broker reaffirmed its buy rating with a $22.00 price target. This implies potential upside of 71% for investors over the next 12 months.

The post These 2 ASX healthcare shares could jump well over 80% appeared first on The Motley Fool Australia.

More reading

• Are these ASX shares too cheap to pass up?
• Telix Pharmaceuticals files European application for brain cancer imaging
• 8 ASX All Ords shares just upgraded to strong buy status
• These are the 10 most shorted ASX shares
• 13 ASX 200 shares hit multi-year lows as the market takes a breather

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The SGH Ltd (ASX: SGH) share price is in focus after the company and Steel Dynamics Inc. confirmed a best and final $32.35 per share offer to acquire BlueScope Steel Ltd (ASX: BSL) valuing BlueScope at $15 billion in cash. The proposal represents a 47% premium to BlueScope’s prior adjusted closing price and a 56% premium to its 52-week average.

What did SGH report?

• Revised non-binding indicative offer of A$32.35 per BlueScope share (total equity value: A$15 billion)
• Offer is 14% above their previous adjusted proposal and 47% above BlueScope’s adjusted prior closing share price
• Full cash consideration for BlueScope shareholders
• SGH intends to retain BlueScope’s Australia and Rest of World operations; Steel Dynamics to acquire North American assets
• Offer subject to regulatory, shareholder, and due diligence conditions

What else do investors need to know?

SGH and Steel Dynamics describe the offer as their best and final proposal unless a superior competing bid emerges for all or a significant portion of BlueScope Steel. The transaction would see BlueScope split, with SGH keeping Australian and global businesses, while Steel Dynamics acquires BlueScope’s North American operations.

Regulatory approvals, due diligence, and formal documentation are still outstanding, but both companies state they are confident about satisfying all required conditions. The revised proposal fits SGH’s capital allocation strategy and supports its plan to further develop BlueScope’s operations outside North America.

What’s next for SGH?

If approved, the acquisition would reshape SGH’s business, positioning it as the owner of BlueScope’s domestic and global segments, while Steel Dynamics would expand into North America. Both SGH and Steel Dynamics remain engaged in discussions and are committed to progressing due diligence, legal documentation, and regulatory processes.

The companies have stated that further updates will be provided to the market as developments arise, and there remains no certainty the offer will result in a completed transaction.

SGH share price snapshot

Over the past 12 months, SGH shares have declined 13%, trailing the S&P/ASX 200 Index (ASX XJO) which has risen 6% over the same period.

View Original Announcement

The post SGH Ltd confirms $32.35 per share BlueScope bid appeared first on The Motley Fool Australia.

More reading

• TechnologyOne upgrades earnings guidance on AI and SaaS+ momentum
• The Lottery Corporation posts steady earnings and dividend for 1H26
• Dexus posts $348.5m half-year profit as property values lift
• Telix Pharmaceuticals files European application for brain cancer imaging
• Netwealth earnings: 24% revenue jump and record inflows

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.